2Bonura F. Prevention ,screening ,and management of osteoporosis: an overview of the current strategies [ J ]. Postgrad Med ,2009, 121:5-17.
3Tournis S. Improvement in bone strength parameters. The role of strontium ranelate [ J ]. J Musculoskelet Neuronal interact,2007,7 : 266-267.
4Seeman E, Eisman JA. Treatment of osteoporosis :why,whom,when and how to treat. The single most important consideration is the individual's absolute risk of fracture [J]. Med J Aust,2004,180: 298-303.
5National Osteoporosis Foundation:Chnician's guide to prevention and treatment of osteoporosis (2008).
6Body JJ.Calcitoni for the long-term prevention and treatment of postmenopausal osteoporosis[J].Bone,2002,30(5):75S.
7Gennari C.Analgesic effect of calcitonin in osteoporosis[J].Bone,2002,30(5):67S.
8Black DM,Cummings SR,karpf DB,et al.Randomised trial of effct of alendronate on risk of fracture in women with existing vertebral fractures[J].Lancet,1996,348(14):1535.
9Pak CY,Sakhaee K,Adams-Huet B,et al.Treatment of postmenopausal osteoporosis with slow-release sodium fluoride:final report of a randomized control trial[J].Ann Intern Med,1995,123(4):401.
10Ray NF,Chan JK,Thamer M,et al.Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995:Report from the National Osteoporosis Foundation[J].J Bone Miner Res,1997,12(1):24.
